462 reports of this reaction
1.4% of all OLAPARIB reports
#14 most reported adverse reaction
MYELODYSPLASTIC SYNDROME is the #14 most commonly reported adverse reaction for OLAPARIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 462 FDA adverse event reports linking OLAPARIB to MYELODYSPLASTIC SYNDROME. This represents approximately 1.4% of all 33,417 adverse event reports for this drug.
Patients taking OLAPARIB who experience myelodysplastic syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELODYSPLASTIC SYNDROME is a less commonly reported adverse event for OLAPARIB, but still significant enough to appear in the safety profile.
In addition to myelodysplastic syndrome, the following adverse reactions have been reported for OLAPARIB:
The following drugs have also been linked to myelodysplastic syndrome in FDA adverse event reports:
MYELODYSPLASTIC SYNDROME has been reported as an adverse event in 462 FDA reports for OLAPARIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELODYSPLASTIC SYNDROME accounts for approximately 1.4% of all adverse event reports for OLAPARIB, making it a notable side effect.
If you experience myelodysplastic syndrome while taking OLAPARIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.